These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 30989614)

  • 1. New mineralocorticoid receptor antagonists: update on their use in chronic kidney disease and heart failure.
    Capelli I; Gasperoni L; Ruggeri M; Donati G; Baraldi O; Sorrenti G; Caletti MT; Aiello V; Cianciolo G; La Manna G
    J Nephrol; 2020 Feb; 33(1):37-48. PubMed ID: 30989614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
    Lerma E; White WB; Bakris G
    Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of mineralocorticoid receptor antagonists in kidney diseases.
    Patel V; Joharapurkar A; Jain M
    Drug Dev Res; 2021 May; 82(3):341-363. PubMed ID: 33179798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
    Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
    Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular and Renal Benefit of Novel Non-steroidal Mineralocorticoid Antagonists in Patients with Diabetes.
    Kintscher U
    Curr Cardiol Rep; 2023 Dec; 25(12):1859-1864. PubMed ID: 37991625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists in heart failure patients with chronic kidney disease: why, when, and how?
    Kassem H; Chatila K
    Curr Opin Nephrol Hypertens; 2020 Mar; 29(2):258-263. PubMed ID: 31833939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Receptor Antagonists and Renal Outcomes in Heart Failure Patients with and without Chronic Kidney Disease.
    Mavrakanas TA; Giannetti N; Sapir-Pichhadze R; Alam A
    Cardiorenal Med; 2020; 10(1):32-41. PubMed ID: 31665724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-steroidal mineralocorticoid receptor antagonists and cardiorenal outcomes in chronic kidney disease.
    Lo KB; Rangaswami J; Vaduganathan M
    Nephrol Dial Transplant; 2023 Mar; 38(4):845-854. PubMed ID: 36472546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease.
    Baran W; Krzemińska J; Szlagor M; Wronka M; Młynarska E; Franczyk B; Rysz J
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
    Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
    Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
    Yao L; Liang X; Wang P
    Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
    Epstein M
    Am J Nephrol; 2021; 52(3):209-216. PubMed ID: 33857953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
    Kolkhof P; Joseph A; Kintscher U
    Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction.
    Lima-Posada I; Stephan Y; Soulié M; Palacios-Ramirez R; Bonnard B; Nicol L; Kolkhof P; Jaisser F; Mulder P
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
    Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
    Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
    Haller H; Bertram A; Stahl K; Menne J
    Curr Hypertens Rep; 2016 Apr; 18(5):41. PubMed ID: 27115525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
    Barrera-Chimal J; Gerarduzzi C; Rossignol P; Jaisser F
    Clin Sci (Lond); 2022 Jun; 136(12):1005-1017. PubMed ID: 35765983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.